K-ras基因突变(mKRAS)可导致非小细胞肺癌(NSCLC)对表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)原发耐药。由于KRAS通路的复杂性使其治疗成为目前热点及难点。以Ras信号通路为靶标的抗肿瘤治疗研究有可能克服EG-FR-TKI原发耐药。本文就有关Ras及其通路上可能治疗靶点的研究进行综述。 K-ras gene mutation (mKRAS) can lead to primary resistance of non-small cell lung cancer (NSCLC) to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Due to the complexity of the KRAS pathway, the treatment has become a hot and difficult issue at present. Anti-cancer therapy targeting Ras signaling pathway is likely to overcome primary resistance to EG-FR-TKI. This article provides an overview of the possible therapeutic targets for Ras and its pathways.